CTPI-2 is primarily used in research settings as a selective inhibitor of the PI3K/Akt/mTOR signaling pathway, which plays a critical role in cell growth, survival, and proliferation. It is commonly applied in oncology studies to investigate cancer cell behavior, particularly in models of solid tumors and hematological malignancies. Due to its ability to cross the blood-brain barrier, CTPI-2 is also utilized in studies targeting brain cancers and neurodegenerative conditions where pathway dysregulation occurs. Its selectivity makes it a valuable tool for probing molecular mechanisms and evaluating therapeutic strategies without broad off-target effects. Researchers use CTPI-2 in vitro and in vivo to assess tumor growth inhibition, apoptosis induction, and potential synergies with other anticancer agents.